Current Report Filing (8-k)
22 Dezember 2022 - 10:46PM
Edgar (US Regulatory)
0000012239
false
--12-31
0000012239
2022-12-22
2022-12-22
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or Section 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
December 22, 2022
Dominari
Holdings Inc.
(Exact name of registrant as specified in its
charter)
| Delaware |
|
000-05576 |
|
52-0849320 |
(State or other jurisdiction
of incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.) |
One
Rockefeller Plaza, 11 th
Floor
New York, NY 10020
(703) 992-9325
(Address, including Zip Code and Telephone
Number, including Area Code, of Principal Executive Offices)
AIkido Pharma Inc.
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions:
| ☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
| Common Stock, $0.0001 par value |
|
DOMH |
|
The Nasdaq Capital Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ☐
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change
in Fiscal Year
Effective December 22, 2022, AIkido Pharma Inc. (the “Company”) filed an amendment to its certificate of incorporation,
as amended, with the Secretary of State of Delaware to change its corporate name from “AIkido Pharma Inc.” to “Dominari
Holdings Inc.” (the “Name Change Amendment”). The Name Change Amendment was previously approved by the Company’s
board of directors on December 5, 2022. The Name Change Amendment is filed as Exhibit 3.1 to this Current Report.
Item 7.01 Regulation FD Disclosure
On December 22, 2022, the
Company issued a press release regarding the change in its corporate name and also a change in the Company’s trading symbol from
“AIKI” to “DOMH”, effective with the opening of trading on December 22, 2022. A copy of such press release is
filed as Exhibit 99.1 to this Current Report.
Item 9.01. Financial Statements and Exhibits.
Set forth below is a list of
Exhibits included as part of this Current Report.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Dated: December 22, 2022 |
DOMINARI HOLDINGS INC. |
| |
|
|
| |
By: |
/s/ Anthony Hayes |
| |
Name: |
Anthony Hayes |
| |
Title: |
Chief Executive Officer |
2
Alkido Pharma (NASDAQ:AIKI)
Historical Stock Chart
Von Dez 2024 bis Jan 2025
Alkido Pharma (NASDAQ:AIKI)
Historical Stock Chart
Von Jan 2024 bis Jan 2025
